Skip to main content
Top
Published in: BMC Gastroenterology 1/2018

Open Access 01-12-2018 | Research article

Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries

Authors: Wenhui Li, Li Jia, Xin Zhao, Xiaoyuan Wu, Hongxia Tang

Published in: BMC Gastroenterology | Issue 1/2018

Login to get access

Abstract

Background

The vertical transmission of HBV from mothers to their infants at birth or in early infancy has a significant role in the endemicity of HBV infection. Tenofovir is one of the most potent anti-HBV agents with a high genetic barrier to resistance. The study is to evaluate the efficacy of tenofovir in preventing perinatal HBV transmission, as well as monitoring safety for mothers and infants.

Methods

PubMed, Embase, Web of Science, and CNKI (National Knowledge Infrastructure, China) database were systematically reviewed for studies that compared the efficacy and safety of tenofovir with other treatments. Pooled estimates were expressed with weight mean difference (WMD) with 95% confidence intervals (95% CIs) and risk ratio (RR) with 95% CIs.

Results

Nine studies involving 1046 pregnant patients met the inclusion criteria and were included in this meta-analysis. Compared with other treatments, tenofovir significantly reduced maternal HBV DNA levels (WMD = 2.33 log10 IU/mL, 95% CI: 1.01, 3.64; P < 0.001), infant HBsAg positivity rate (RR = 0.25, 95% CI: 0.16, 0.38; P < 0.001), infant HBeAg positivity rate (RR = 0.26, 95% CI: 0.14, 0.48; P < 0.001), infant HBV DNA positivity rate (RR = 0.15, 95% CI: 0.07, 0.31; P < 0.001), and immunoprophylaxis failure rate (RR = 0.31, 95% CI: 0.13, 0.73; P = 0.008). Moreover, maternal and infant safety profiles, including ALT, CK, and Cr were comparable between tenofovir and other treatment groups.

Conclusion

Based on the current evidence, our study suggested that tenofovir significantly reduced the rate of vertical transmission of HBV, as well as the HBV DNA levels in HBV-infected mothers. Moreover, tenofovir was safe and tolerable for both mothers and their infants.
Literature
1.
go back to reference EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRef EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–85.CrossRef
3.
go back to reference Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. New Engl J Med. 1975;292:771–4.CrossRefPubMed Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. New Engl J Med. 1975;292:771–4.CrossRefPubMed
4.
go back to reference Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology (Baltimore, Md). 1983;3:135–41.CrossRef Beasley RP, Hwang LY, Stevens CE, Lin CC, Hsieh FJ, Wang KY, et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology (Baltimore, Md). 1983;3:135–41.CrossRef
5.
go back to reference Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, et al. Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10:1287–93.CrossRefPubMed Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, et al. Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10:1287–93.CrossRefPubMed
6.
go back to reference Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215–21.CrossRefPubMed Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215–21.CrossRefPubMed
7.
go back to reference Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005;11:7953–7.CrossRefPubMed Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005;11:7953–7.CrossRefPubMed
8.
go back to reference Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer I. 2009;101:1348–55.CrossRef Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer I. 2009;101:1348–55.CrossRef
9.
go back to reference Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142:773–81. e2CrossRefPubMed Chen HL, Lin LH, Hu FC, Lee JT, Lin WT, Yang YJ, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology. 2012;142:773–81. e2CrossRefPubMed
10.
go back to reference Song YM, Sung J, Yang S, Choe YH, Chang YS, Park WS. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr. 2007;166:813–8.CrossRefPubMed Song YM, Sung J, Yang S, Choe YH, Chang YS, Park WS. Factors associated with immunoprophylaxis failure against vertical transmission of hepatitis B virus. Eur J Pediatr. 2007;166:813–8.CrossRefPubMed
11.
go back to reference Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis. 1994;170:1418–23.CrossRefPubMed Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis. 1994;170:1418–23.CrossRefPubMed
12.
13.
go back to reference Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepatitis. 2009;16:94–103.CrossRef Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepatitis. 2009;16:94–103.CrossRef
14.
go back to reference van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepatitis. 2003;10:294–7.CrossRef van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepatitis. 2003;10:294–7.CrossRef
15.
go back to reference Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology (Baltimore, Md). 1998;27:1711–6.CrossRef Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology (Baltimore, Md). 1998;27:1711–6.CrossRef
16.
go back to reference Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol H. 2012;10:520–6.CrossRef Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol H. 2012;10:520–6.CrossRef
17.
go back to reference Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Digestive Dis Sci. 2015;60:1457–64.CrossRef Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Digestive Dis Sci. 2015;60:1457–64.CrossRef
18.
go back to reference Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology (Baltimore, Md). 2014;60:468–76.CrossRef Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology (Baltimore, Md). 2014;60:468–76.CrossRef
19.
go back to reference Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Digestive Dis Sci. 2012;57:2423–9.CrossRef Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Digestive Dis Sci. 2012;57:2423–9.CrossRef
20.
go back to reference Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502–7.CrossRefPubMed Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502–7.CrossRefPubMed
21.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 2009;339:b2535.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical research ed). 2009;339:b2535.CrossRef
22.
go back to reference Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther. 2005;85:257–68.PubMed Sim J, Wright CC. The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther. 2005;85:257–68.PubMed
23.
go back to reference Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 2011;343:d5928.CrossRefPubMedCentral Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 2011;343:d5928.CrossRefPubMedCentral
24.
go back to reference Wells G, Shea B, O’connell D, Peterson J, Welch V. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. In: 3rd Symposium on Systematic Reviews: Beyond the Basics; 2000. p. 3–5. Wells G, Shea B, O’connell D, Peterson J, Welch V. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. In: 3rd Symposium on Systematic Reviews: Beyond the Basics; 2000. p. 3–5.
25.
go back to reference Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327:557–60.CrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327:557–60.CrossRef
26.
27.
go back to reference Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer I. 1959;22:719–48. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer I. 1959;22:719–48.
28.
go back to reference Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMed
29.
go back to reference Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315:629–34.CrossRef Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed). 1997;315:629–34.CrossRef
30.
go back to reference Sellier PO, Maylin S, Bercot B, Chopin D, Lopes A, Simoneau G, et al. Prospective interventional study of tenofovir in pregnancy to prevent vertical transmission of hepatitis B in highly viremic women. Eur J Gastroenterol Hepatol. 2017;29:259–63.CrossRefPubMed Sellier PO, Maylin S, Bercot B, Chopin D, Lopes A, Simoneau G, et al. Prospective interventional study of tenofovir in pregnancy to prevent vertical transmission of hepatitis B in highly viremic women. Eur J Gastroenterol Hepatol. 2017;29:259–63.CrossRefPubMed
31.
go back to reference Wang J, Liu J, Qi C, Yan T, Cao F, Jin L, et al. Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV. Antiviral Ther. 2015;20:681–7.CrossRef Wang J, Liu J, Qi C, Yan T, Cao F, Jin L, et al. Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV. Antiviral Ther. 2015;20:681–7.CrossRef
32.
go back to reference Chamroonkul N, Piratvisuth T. Hepatitis B during pregnancy in endemic areas: screening, treatment, and prevention of mother-to-child transmission. Paediatric Drugs. 2017;19:173–81.CrossRefPubMed Chamroonkul N, Piratvisuth T. Hepatitis B during pregnancy in endemic areas: screening, treatment, and prevention of mother-to-child transmission. Paediatric Drugs. 2017;19:173–81.CrossRefPubMed
33.
go back to reference Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–43.CrossRefPubMed Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–43.CrossRefPubMed
34.
go back to reference Virine B, Osiowy C, Gao S, Wang T, Castillo E, Martin SR, et al. Hepatitis B virus (HBV) variants in untreated and Tenofovir treated chronic hepatitis B (CHB) patients during pregnancy and post-partum follow-up. PLoS One. 2015;10:e0140070.CrossRefPubMedPubMedCentral Virine B, Osiowy C, Gao S, Wang T, Castillo E, Martin SR, et al. Hepatitis B virus (HBV) variants in untreated and Tenofovir treated chronic hepatitis B (CHB) patients during pregnancy and post-partum follow-up. PLoS One. 2015;10:e0140070.CrossRefPubMedPubMedCentral
35.
go back to reference Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, et al. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis. 2016;16:393.CrossRefPubMedPubMedCentral Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, et al. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis. 2016;16:393.CrossRefPubMedPubMedCentral
36.
go back to reference Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology (Baltimore, Md). 2015;62:375–86.CrossRef Chen HL, Lee CN, Chang CH, Ni YH, Shyu MK, Chen SM, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology (Baltimore, Md). 2015;62:375–86.CrossRef
37.
go back to reference Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. New Engl J Medicine. 2016;374:2324–34.CrossRef Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. New Engl J Medicine. 2016;374:2324–34.CrossRef
38.
go back to reference Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol. 2013;19:9377–82.CrossRefPubMedPubMedCentral Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol. 2013;19:9377–82.CrossRefPubMedPubMedCentral
39.
go back to reference Samadi Kochaksaraei G, Castillo E, Osman M, Simmonds K, Scott AN, Oshiomogho JI, et al. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepatitis. 2016;23:15–22.CrossRef Samadi Kochaksaraei G, Castillo E, Osman M, Simmonds K, Scott AN, Oshiomogho JI, et al. Clinical course of 161 untreated and tenofovir-treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region. J Viral Hepatitis. 2016;23:15–22.CrossRef
40.
go back to reference Chen WJ, Song SR, He H, Liang Q. Efficacy and safety of tenofovir, telbivudine in pregnancy to prevent perinatal transmission of hepatitis B virus. Shandong Med J. 2017;57:73–5. Chen WJ, Song SR, He H, Liang Q. Efficacy and safety of tenofovir, telbivudine in pregnancy to prevent perinatal transmission of hepatitis B virus. Shandong Med J. 2017;57:73–5.
41.
go back to reference Wan JY, Cai QE, Wang M. Efficacy and safety of tenofovir on blocking mother to child transmission of hepatitis B virus in virus high load pregenant women. China Tropical Med. 2017;17:828–30. Wan JY, Cai QE, Wang M. Efficacy and safety of tenofovir on blocking mother to child transmission of hepatitis B virus in virus high load pregenant women. China Tropical Med. 2017;17:828–30.
42.
go back to reference Qi WY, Zhao ZJ, Liu JQ. Clinical study on the effectiveness of tenofovir on blocking mother to child transmission of hepatitis B virus in pregnant women with chronic hepatitis B. Chinese J Med Guide. 2017;19:176–7. Qi WY, Zhao ZJ, Liu JQ. Clinical study on the effectiveness of tenofovir on blocking mother to child transmission of hepatitis B virus in pregnant women with chronic hepatitis B. Chinese J Med Guide. 2017;19:176–7.
43.
go back to reference Deng J, Chen Y, Jia G. Curative effect of tenofovir disoproxil in the treatment of hepatitis B pregnant women and its effect on blocking mother to child transmission of hepatitis B virus. China Modern Doctor. 2017;55:24–6. Deng J, Chen Y, Jia G. Curative effect of tenofovir disoproxil in the treatment of hepatitis B pregnant women and its effect on blocking mother to child transmission of hepatitis B virus. China Modern Doctor. 2017;55:24–6.
44.
go back to reference Nguyen V, Tan PK, Greenup AJ, Glass A, Davison S, Samarasinghe D, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharm Therap. 2014;39:1225–34.CrossRef Nguyen V, Tan PK, Greenup AJ, Glass A, Davison S, Samarasinghe D, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharm Therap. 2014;39:1225–34.CrossRef
Metadata
Title
Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries
Authors
Wenhui Li
Li Jia
Xin Zhao
Xiaoyuan Wu
Hongxia Tang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2018
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-018-0847-2

Other articles of this Issue 1/2018

BMC Gastroenterology 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.